Cargando…

Incidence and Predictors of Ventricular Arrhythmias in Transthyretin Amyloid Cardiomyopathy

Background: Wild-type transthyretin amyloid cardiomyopathy (wtATTR-CM) is characterized by heart failure, conduction abnormalities and arrhythmias. The incidence of ventricular arrhythmias, particularly ventricular tachycardias (VTs), in wtATTR-CM is unclear. With the development of targeted therapi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Knoll, Katharina, Fuchs, Patrick, Weidmann, Isabel, Altunkas, Fatih, Voss, Stephanie, Lennerz, Carsten, Kolb, Christof, Kessler, Thorsten, Schunkert, Heribert, Reinhard, Wibke, Groß, Stefan, Trenkwalder, Teresa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380522/ https://www.ncbi.nlm.nih.gov/pubmed/37510739 http://dx.doi.org/10.3390/jcm12144624

Ejemplares similares

Left ventricular hypertrophy, dilatation and ejection fractions predict ventricular tachycardia in amyloid transthyretin cardiomyopathy
por: Knoll, K, et al.
Publicado: (2023)

Novel frame-shift mutation in PKP2 associated with arrhythmogenic right ventricular cardiomyopathy: a case report
por: Trenkwalder, Teresa, et al.
Publicado: (2015)

Combined telemonitoring and telecoaching for heart failure improves outcome
por: Knoll, Katharina, et al.
Publicado: (2023)

Diagnosis of Transthyretin Amyloid Cardiomyopathy
por: Hafeez, Adam S., et al.
Publicado: (2020)

Hereditary transthyretin amyloid cardiomyopathy
por: Zheng, Yiliang, et al.
Publicado: (2023)

Recovery of sinus rhythm by tafamidis in patients with wild-type transthyretin amyloid cardiomyopathy with atrial arrhythmias
por: Isotani, Yoshitaka, et al.
Publicado: (2022)

Transthyretin Stabilizers and Seeding Inhibitors as Therapies for Amyloid Transthyretin Cardiomyopathy
por: Morfino, Paolo, et al.
Publicado: (2023)

Speckle Tracking and Transthyretin Amyloid Cardiomyopathy
por: Rocha, Alexandre Marins, et al.
Publicado: (2017)

Systemic embolism in amyloid transthyretin cardiomyopathy
por: Vilches, Silvia, et al.
Publicado: (2022)

Transthyretin Amyloid Cardiomyopathy: Impact of Transthyretin Amyloid Deposition in Myocardium on Cardiac Morphology and Function
por: Nakano, Tomoya, et al.
Publicado: (2022)

Multi-modality imaging in transthyretin amyloid cardiomyopathy
por: Traynor, Bryan Paul, et al.
Publicado: (2019)

Standardising Care and Treatment of Transthyretin Amyloid Cardiomyopathy
por: Fontana, Marianna, et al.
Publicado: (2023)

Telemedical monitoring and coaching improves survival and hospitalisation rates in heart failure
por: Knoll, K, et al.
Publicado: (2022)

Multiple focal atrial tachycardia as a characteristic finding of intractable arrhythmia associated with wild-type transthyretin amyloid cardiomyopathy
por: Kanazawa, Hisanori, et al.
Publicado: (2022)

Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey
por: Nativi-Nicolau, Jose, et al.
Publicado: (2021)

Effect of Tafamidis on Serum Transthyretin Levels in Non-Trial Patients With Transthyretin Amyloid Cardiomyopathy
por: Falk, Rodney H., et al.
Publicado: (2021)

Transthyretin amyloid cardiomyopathy: An uncharted territory awaiting discovery
por: Porcari, Aldostefano, et al.
Publicado: (2020)

Initial Experience With Tafamidis Treatment for Transthyretin Amyloid Cardiomyopathy
por: Nakamura, Makiko, et al.
Publicado: (2020)

Nationwide prevalence and characteristics of transthyretin amyloid cardiomyopathy in Sweden
por: Lauppe, Rosa Elisabeth, et al.
Publicado: (2021)

Healthcare resource use of patients with transthyretin amyloid cardiomyopathy
por: Lauppe, Rosa, et al.
Publicado: (2022)

Oral Therapy for the Treatment of Transthyretin-Related Amyloid Cardiomyopathy
por: Nuvolone, Mario, et al.
Publicado: (2022)

Extrapolation of Survival Benefits in Patients with Transthyretin Amyloid Cardiomyopathy Receiving Tafamidis: Analysis of the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial
por: Li, Benjamin, et al.
Publicado: (2020)

Transthyretin amyloid cardiomyopathy in women: frequency, characteristics, and diagnostic challenges
por: Bruno, Marianna, et al.
Publicado: (2020)

A Systematic Review of Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy
por: Singh, Bishnu Mohan, et al.
Publicado: (2021)

Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy
por: Elliott, Perry, et al.
Publicado: (2021)

Treatment of Transthyretin Amyloid Cardiomyopathy: The Current Options, the Future, and the Challenges
por: Tschöpe, Carsten, et al.
Publicado: (2022)

Targeting ADAMTS-7: a vaccination against atherosclerosis – and its complications?
por: Kessler, Thorsten, et al.
Publicado: (2023)

Inhibitors of the renin–angiotensin system and SARS-CoV-2 infection
por: Kessler, Thorsten, et al.
Publicado: (2020)

Coronary Artery Disease Genetics Enlightened by Genome-Wide Association Studies
por: Kessler, Thorsten, et al.
Publicado: (2021)

Clinical characteristics and prognosis of Chinese patients with hereditary transthyretin amyloid cardiomyopathy
por: He, Shan, et al.
Publicado: (2019)

Best Practices for Prognostic Evaluation of a Patient With Transthyretin Amyloid Cardiomyopathy
por: Feng, Kent Y., et al.
Publicado: (2019)

Clinical recommendations to diagnose and monitor patients with transthyretin amyloid cardiomyopathy in Asia
por: Lin, Weiqin, et al.
Publicado: (2022)

Prevalence, characteristics, and mortality of patients with transthyretin amyloid cardiomyopathy in the Nordic countries
por: Lauppe, Rosa, et al.
Publicado: (2022)

Endothelial Function Is Preserved in Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy
por: Hashimoto, Yu, et al.
Publicado: (2023)

Health‐related quality of life among transthyretin amyloid cardiomyopathy patients
por: Eldhagen, Per, et al.
Publicado: (2023)

Monitoring tafamidis treatment with quantitative SPECT/CT in transthyretin amyloid cardiomyopathy
por: Rettl, René, et al.
Publicado: (2023)

Treating amyloid transthyretin cardiomyopathy: lessons learned from clinical trials
por: Tomasoni, Daniela, et al.
Publicado: (2023)

Correlation Between Cardiac Images, Biomarkers, and Amyloid Load in Wild‐Type Transthyretin Amyloid Cardiomyopathy
por: Morioka, Mami, et al.
Publicado: (2022)

Treatment of transthyretin (TTR) amyloid cardiomyopathy with an antisense oligonucleotide inhibitor of TTR synthesis
por: Benson, Merrill D, et al.
Publicado: (2015)

Clinical characteristics and natural history of wild‐type transthyretin amyloid cardiomyopathy in Japan
por: Yamada, Toshihiro, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_98i4o4dp82papdkgoq9stc4v05